| scholarly article | Q13442814 |
| P2093 | author name string | Jan Nilsson | |
| Xiaoning Zhao | |||
| Prediman K Shah | |||
| Gunilla Nordin Fredrikson | |||
| Bojan Cercek | |||
| Kuang-Yuh Chyu | |||
| Paul C Dimayuga | |||
| Juliana Yano | |||
| Odette S Reyes | |||
| Stephanie M Babbidge | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypercholesterolemia | Q762713 |
| inflammation | Q101991 | ||
| immunization | Q1415366 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 1982-1989 | |
| P577 | publication date | 2005-11-02 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice | |
| P478 | volume | 338 |
| Q89186695 | A clinically applicable adjuvant for an atherosclerosis vaccine in mice |
| Q36547962 | A potent multivalent vaccine for modulation of immune system in atherosclerosis: an in silico approach |
| Q40119196 | A vaccine against atherosclerosis: myth or reality? |
| Q42679444 | Adsorption of low-density lipoprotein, its oxidation, and subsequent binding of specific recombinant antibodies: An in situ ellipsometric study |
| Q37709623 | Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases |
| Q37415733 | Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. |
| Q38346930 | Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges |
| Q37138017 | Autoimmunity in atherosclerosis: a protective response losing control? |
| Q91650985 | B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apolipoprotein E deficient mice |
| Q33761718 | CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe⁻(/)⁻ mice |
| Q28732168 | CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide |
| Q38137846 | Can we vaccinate against atherosclerosis? |
| Q38218096 | Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects |
| Q46457217 | High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction |
| Q41627194 | Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis |
| Q36945213 | Immunization for atherosclerosis |
| Q35174901 | Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoE-/- mice |
| Q30361151 | Inflammation modulation and cardiovascular disease prevention. |
| Q33805176 | Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics |
| Q64915291 | Low-Density Lipoprotein-Reactive T Cells Regulate Plasma Cholesterol Levels and Development of Atherosclerosis in Humanized Hypercholesterolemic Mice. |
| Q38210609 | Multiple potential roles for B cells in atherosclerosis |
| Q92820698 | Opportunities for an atherosclerosis vaccine: From mice to humans |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q58905662 | Pro- and Anti-Inflammatory Cytokine Networks in Atherosclerosis |
| Q37835406 | Progress and future opportunities in the development of vaccines against atherosclerosis |
| Q46859383 | Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice |
| Q38593722 | The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials |
| Q33641227 | Vaccine against arteriosclerosis: an update |
| Q38089941 | Vaccines against atherosclerosis |
Search more.